CHU Montpellier, Hôpital Gui-de-Chauliac, Service de Neurologie, Unité du Sommeil, Centre National de Référence pour la Narcolepsie, Montpellier, France.
Institute Neurosciences of Montellier, Université de Montpellier, INSERM, Montpellier, France.
J Clin Sleep Med. 2022 Feb 1;18(2):617-629. doi: 10.5664/jcsm.9682.
To assess the responsiveness of the Idiopathic Hypersomnia Severity Scale (IHSS) to medications and estimate the minimum clinically important difference, to report clinically relevant score ranges, and to confirm its psychometric properties and whether items need to be weighted in drug-free and treated patients with idiopathic hypersomnia (IH).
Two-hundred twenty-six (166 drug-free and 60 treated) patients with IH (cross-sectional sample) completed the 14-item IHSS to quantify the severity of the 3 major IH symptoms (excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia) and consequences; 77 untreated patients were evaluated again after treatment (longitudinal sample). Patients filled in the Epworth Sleepiness Scale, Beck Depression Inventory II, and European Quality of Life questionnaires.
The IHSS confirmed adequate psychometric properties with a factor analysis indicating a 3-component solution. IHSS total score was lower in treated than untreated patients, with a mean difference of 4-5 points in the cross-sectional and longitudinal samples. Distribution-based methods were used to estimate that 4 points represented the minimum clinically important difference. Four severity levels were defined with between-group differences related to treatment. The probability of having severe sleepiness, depressive symptoms, and low quality of life increased with the severity level. Our results showed that IHSS item-weighting was not necessary.
The IHSS is a valid and reliable tool to quantify IH symptoms, with 4 severity score levels of clinical importance. The IHSS has adequate psychometric properties and can detect symptom changes after treatment. These findings should stimulate its use in clinical settings and in research studies.
Rassu AL, Evangelista E, Barateau L, et al. Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. . 2022;18(2):617-629.
评估特发性嗜睡症严重程度量表(IHSS)对药物的反应性,并估计最小临床重要差异,报告具有临床意义的评分范围,并确认其心理测量特性以及在未经药物治疗和接受治疗的特发性嗜睡症(IH)患者中是否需要对项目进行加权。
226 名(166 名未接受药物治疗和 60 名接受治疗)特发性嗜睡症患者(横断面样本)完成了 14 项 IHSS,以量化 3 种主要 IH 症状(白天过度嗜睡、延长夜间睡眠时间和睡眠惯性)和后果的严重程度;77 名未经治疗的患者在治疗后再次进行评估(纵向样本)。患者填写了 Epworth 嗜睡量表、贝克抑郁量表 II 和欧洲生活质量问卷。
IHSS 通过因素分析确认了足够的心理测量特性,表明存在 3 个组成部分的解决方案。与未经治疗的患者相比,接受治疗的患者 IHSS 总分较低,横断面和纵向样本中的平均差异为 4-5 分。基于分布的方法用于估计 4 分代表最小临床重要差异。使用 4 个严重程度水平定义,组间差异与治疗相关。严重嗜睡、抑郁症状和生活质量低的可能性随着严重程度的增加而增加。我们的结果表明,IHSS 项目加权不是必需的。
IHSS 是一种有效且可靠的工具,可用于量化 IH 症状,具有 4 个具有临床重要性的严重程度评分水平。IHSS 具有足够的心理测量特性,可以检测治疗后的症状变化。这些发现应该刺激其在临床环境和研究中的使用。